# Optimum Treatment for Drug-Resistant Hypertension

> **NCT02369081** · PHASE4 · UNKNOWN · sponsor: **University of Cambridge** · enrollment: 348 (actual)

## Conditions studied

- Hypertension, Resistant to Conventional Therapy

## Interventions

- **DRUG:** Spironolactone
- **DRUG:** Bisoprolol
- **DRUG:** Doxazosin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02369081
- **Lead sponsor:** University of Cambridge
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-05
- **Primary completion:** 2015-07
- **Final completion:** 2015-08
- **Target enrollment:** 348 (ACTUAL)
- **Last updated:** 2015-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02369081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02369081, "Optimum Treatment for Drug-Resistant Hypertension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02369081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*